| 000 | 01908 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250516140153.0 | ||
| 264 | 0 | _c20140829 | |
| 008 | 201408s 0 0 eng d | ||
| 022 | _a1938-2723 | ||
| 024 | 7 |
_a10.1177/1076029613479819 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSadeghi, Nasiredin | |
| 245 | 0 | 0 |
_aTissue factor-mediated activation of the prothrombin complex concentrate (PCC) is differently inhibited by dabigatran, rivaroxaban, and apixaban: potential clinical implication. _h[electronic resource] |
| 260 |
_bClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis _c |
||
| 300 |
_a589-99 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAnticoagulants _xpharmacology |
| 650 | 0 | 4 |
_aBenzimidazoles _xpharmacology |
| 650 | 0 | 4 |
_aBlood Coagulation Factors _xantagonists & inhibitors |
| 650 | 0 | 4 | _aDabigatran |
| 650 | 0 | 4 | _aElectrophoresis, Polyacrylamide Gel |
| 650 | 0 | 4 |
_aFactor Xa _xmetabolism |
| 650 | 0 | 4 | _aFactor Xa Inhibitors |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMorpholines _xpharmacology |
| 650 | 0 | 4 |
_aProthrombin _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aPyrazoles _xpharmacology |
| 650 | 0 | 4 |
_aPyridones _xpharmacology |
| 650 | 0 | 4 | _aRivaroxaban |
| 650 | 0 | 4 |
_aThiophenes _xpharmacology |
| 650 | 0 | 4 |
_aThrombin _xbiosynthesis |
| 650 | 0 | 4 |
_aThromboplastin _xmetabolism |
| 650 | 0 | 4 |
_abeta-Alanine _xanalogs & derivatives |
| 700 | 1 | _aKahn, Daniel | |
| 700 | 1 | _aJeske, Walter | |
| 700 | 1 | _aHoppensteadt, Debra | |
| 700 | 1 | _aFareed, Jawed | |
| 773 | 0 |
_tClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis _gvol. 19 _gno. 6 _gp. 589-99 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1177/1076029613479819 _zAvailable from publisher's website |
| 999 |
_c22555701 _d22555701 |
||